JP2012504393A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012504393A5 JP2012504393A5 JP2011529472A JP2011529472A JP2012504393A5 JP 2012504393 A5 JP2012504393 A5 JP 2012504393A5 JP 2011529472 A JP2011529472 A JP 2011529472A JP 2011529472 A JP2011529472 A JP 2011529472A JP 2012504393 A5 JP2012504393 A5 JP 2012504393A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- cell
- seq
- tumor
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 35
- 210000004027 cell Anatomy 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 239000013604 expression vector Substances 0.000 claims 6
- 208000005017 glioblastoma Diseases 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102100028743 CAP-Gly domain-containing linker protein 2 Human genes 0.000 claims 3
- 102100024074 Dystrobrevin alpha Human genes 0.000 claims 3
- 206010018338 Glioma Diseases 0.000 claims 3
- 101000767059 Homo sapiens CAP-Gly domain-containing linker protein 2 Proteins 0.000 claims 3
- 101001053689 Homo sapiens Dystrobrevin alpha Proteins 0.000 claims 3
- 101001108364 Homo sapiens Neuronal cell adhesion molecule Proteins 0.000 claims 3
- 101000633503 Homo sapiens Nuclear receptor subfamily 2 group E member 1 Proteins 0.000 claims 3
- 101000600766 Homo sapiens Podoplanin Proteins 0.000 claims 3
- 208000000172 Medulloblastoma Diseases 0.000 claims 3
- 206010029260 Neuroblastoma Diseases 0.000 claims 3
- 102100021852 Neuronal cell adhesion molecule Human genes 0.000 claims 3
- 102100029534 Nuclear receptor subfamily 2 group E member 1 Human genes 0.000 claims 3
- 102100037265 Podoplanin Human genes 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 239000003550 marker Substances 0.000 claims 3
- 206010003571 Astrocytoma Diseases 0.000 claims 2
- 206010014967 Ependymoma Diseases 0.000 claims 2
- 208000003098 Ganglion Cysts Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 2
- 201000000582 Retinoblastoma Diseases 0.000 claims 2
- 208000005400 Synovial Cyst Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000014509 gene expression Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000027831 neuroepithelial neoplasm Diseases 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 2
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 claims 1
- 208000004139 Choroid Plexus Neoplasms Diseases 0.000 claims 1
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 201000004066 Ganglioglioma Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 1
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 1
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 208000033383 Neuroendocrine tumor of pancreas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000007641 Pinealoma Diseases 0.000 claims 1
- 206010057846 Primitive neuroectodermal tumour Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 108010002687 Survivin Proteins 0.000 claims 1
- 206010043276 Teratoma Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000005476 astroblastoma Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 208000025997 central nervous system neoplasm Diseases 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001886 ciliary effect Effects 0.000 claims 1
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 claims 1
- 238000004040 coloring Methods 0.000 claims 1
- 230000009260 cross reactivity Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000010932 epithelial neoplasm Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 210000004602 germ cell Anatomy 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 210000001161 mammalian embryo Anatomy 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 201000004058 mixed glioma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 claims 1
- 230000008520 organization Effects 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20080017305 EP2172211B1 (en) | 2008-10-01 | 2008-10-01 | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
| EP08017305.7 | 2008-10-01 | ||
| EP08017921.1 | 2008-10-13 | ||
| EP08017921.1A EP2172212B1 (en) | 2008-10-01 | 2008-10-13 | Novel immunotherapy against several tumors including neuronal and brain tumors |
| US10592808P | 2008-10-16 | 2008-10-16 | |
| US61/105,928 | 2008-10-16 | ||
| PCT/EP2009/006980 WO2010037514A2 (en) | 2008-10-01 | 2009-09-28 | Novel immunotherapy against several tumors including neuronal and brain tumors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014126001A Division JP5883476B2 (ja) | 2008-10-01 | 2014-06-19 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012504393A JP2012504393A (ja) | 2012-02-23 |
| JP2012504393A5 true JP2012504393A5 (enExample) | 2013-05-23 |
| JP5855940B2 JP5855940B2 (ja) | 2016-02-09 |
Family
ID=40342382
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011529472A Expired - Fee Related JP5855940B2 (ja) | 2008-10-01 | 2009-09-28 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2011529471A Expired - Fee Related JP5753783B2 (ja) | 2008-10-01 | 2009-09-28 | 神経膠芽細胞腫（ｇｂｍ）およびその他の癌の治療に用いる腫瘍関連ペプチド組成物と関連抗癌ワクチン |
| JP2014126001A Expired - Fee Related JP5883476B2 (ja) | 2008-10-01 | 2014-06-19 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2015200021A Active JP6150859B2 (ja) | 2008-10-01 | 2015-10-08 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016021002A Expired - Fee Related JP6214066B2 (ja) | 2008-10-01 | 2016-02-05 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016136519A Expired - Fee Related JP6297632B2 (ja) | 2008-10-01 | 2016-07-11 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016136515A Expired - Fee Related JP6367266B2 (ja) | 2008-10-01 | 2016-07-11 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016136518A Expired - Fee Related JP6294914B2 (ja) | 2008-10-01 | 2016-07-11 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016136517A Expired - Fee Related JP6294913B2 (ja) | 2008-10-01 | 2016-07-11 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016136516A Pending JP2017029135A (ja) | 2008-10-01 | 2016-07-11 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
Family Applications After (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011529471A Expired - Fee Related JP5753783B2 (ja) | 2008-10-01 | 2009-09-28 | 神経膠芽細胞腫（ｇｂｍ）およびその他の癌の治療に用いる腫瘍関連ペプチド組成物と関連抗癌ワクチン |
| JP2014126001A Expired - Fee Related JP5883476B2 (ja) | 2008-10-01 | 2014-06-19 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2015200021A Active JP6150859B2 (ja) | 2008-10-01 | 2015-10-08 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016021002A Expired - Fee Related JP6214066B2 (ja) | 2008-10-01 | 2016-02-05 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016136519A Expired - Fee Related JP6297632B2 (ja) | 2008-10-01 | 2016-07-11 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016136515A Expired - Fee Related JP6367266B2 (ja) | 2008-10-01 | 2016-07-11 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016136518A Expired - Fee Related JP6294914B2 (ja) | 2008-10-01 | 2016-07-11 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016136517A Expired - Fee Related JP6294913B2 (ja) | 2008-10-01 | 2016-07-11 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016136516A Pending JP2017029135A (ja) | 2008-10-01 | 2016-07-11 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
Country Status (24)
| Country | Link |
|---|---|
| US (19) | US8318677B2 (enExample) |
| EP (12) | EP2172211B1 (enExample) |
| JP (10) | JP5855940B2 (enExample) |
| KR (6) | KR101687840B1 (enExample) |
| CN (3) | CN106986919A (enExample) |
| AU (2) | AU2009300088B2 (enExample) |
| BR (2) | BRPI0920791B8 (enExample) |
| CA (9) | CA2936982C (enExample) |
| CY (11) | CY1116302T1 (enExample) |
| DK (12) | DK2172211T3 (enExample) |
| EA (3) | EA023013B1 (enExample) |
| ES (12) | ES2536465T3 (enExample) |
| HR (12) | HRP20160915T1 (enExample) |
| HU (11) | HUE031030T2 (enExample) |
| LT (10) | LT2172212T (enExample) |
| MX (3) | MX2011003539A (enExample) |
| NZ (4) | NZ591855A (enExample) |
| PL (12) | PL2172211T3 (enExample) |
| PT (12) | PT2172211E (enExample) |
| RS (12) | RS53782B1 (enExample) |
| SI (12) | SI2172211T1 (enExample) |
| TR (2) | TR201900809T4 (enExample) |
| UA (3) | UA110599C2 (enExample) |
| WO (2) | WO2010037513A1 (enExample) |
Families Citing this family (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006023598A2 (en) | 2004-08-19 | 2006-03-02 | University Of Maryland, Baltimore | Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer |
| WO2006034334A2 (en) | 2004-09-21 | 2006-03-30 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response |
| HRP20150820T1 (xx) * | 2007-07-27 | 2015-09-11 | Immatics Biotechnologies Gmbh | Nova imunoterapija protiv neuronskih tumora i tumora mozga |
| DE602008000891D1 (de) | 2008-04-30 | 2010-05-12 | Immatics Biotechnologies Gmbh | Neuartige Formulierungen von Tumor-assoziierten Peptiden, welche an menschliche Leukozytenantigene der Klasse I oder II für Impfungen binden |
| EP2119726B2 (en) | 2008-05-14 | 2017-11-29 | Immatics Biotechnologies GmbH | Novel and powerful MHC-class II peptides derived from survivin and neurocan |
| EP2172211B1 (en) * | 2008-10-01 | 2014-12-03 | Immatics Biotechnologies GmbH | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
| TW201124530A (en) * | 2009-12-01 | 2011-07-16 | Oncotherapy Science Inc | IMP-3 oligopeptides and vaccines including the same |
| SE535982C2 (sv) * | 2009-12-15 | 2013-03-19 | Theravac Pharmaceuticals Ab | Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| AU2015200751B2 (en) * | 2010-03-19 | 2016-11-10 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| ES2930809T3 (es) * | 2010-08-24 | 2022-12-22 | Univ Pittsburgh Commonwealth Sys Higher Education | Vacunas contra el cáncer cerebral basadas en el péptido receptor de interleucina-13 alfa 2 |
| WO2012075490A2 (en) * | 2010-12-03 | 2012-06-07 | Duke University | Anti-podoplanin antibodies and methods of use |
| SG191154A1 (en) * | 2010-12-14 | 2013-07-31 | Immatics Biotechnologies Gmbh | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
| US20140154269A1 (en) * | 2011-04-26 | 2014-06-05 | The Methodist Hospital Research Institute | Targeted nanovectors and their use for treatment of brain tumors |
| AU2012308302A1 (en) | 2011-09-14 | 2014-03-20 | Northwestern University | Nanoconjugates able to cross the blood-brain barrier |
| GB201120779D0 (en) | 2011-12-02 | 2012-01-11 | Immodulon Therapeutics Ltd | Cancer therapy |
| MX385227B (es) | 2012-01-20 | 2025-03-14 | Del Mar Pharmaceuticals | Uso de hexitoles sustituidos que incluyen dianhidrogalactitol y análogos para tratar enfermedad neoplásica y células madre de cáncer que incluyen glioblastoma multiforme y meduloblastoma. |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| CN103372217B (zh) * | 2012-04-28 | 2014-12-10 | 中国科学院深圳先进技术研究院 | 聚合物纳米载体制剂及其制备方法和应用 |
| CA2911191C (en) * | 2012-05-16 | 2023-02-28 | Stemline Therapeutics, Inc. | Cancer stem cell targeted cancer vaccines |
| CN112587658A (zh) * | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| TWI777195B (zh) * | 2013-08-05 | 2022-09-11 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（三） |
| HRP20211852T1 (hr) | 2013-08-05 | 2022-03-18 | Immatics Biotechnologies Gmbh | Nova imunoterapija protiv nekoliko tumora, poput raka pluća, uključujući nsclc |
| GB201319446D0 (en) * | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| MX2019013161A (es) * | 2013-11-04 | 2020-02-03 | Immatics Biotechnologies Gmbh | Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales. |
| CN104698059B (zh) * | 2013-12-04 | 2017-07-21 | 苏州中赢医疗科技有限公司 | 一种脑胶质瘤肿瘤标志物及其应用 |
| GB201322725D0 (en) | 2013-12-20 | 2014-02-05 | Immodulon Therapeutics Ltd | Cancer therapy |
| EP3092049A1 (en) | 2014-01-08 | 2016-11-16 | Flodesign Sonics Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| KR101503341B1 (ko) * | 2014-03-12 | 2015-03-18 | 국립암센터 | 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법 |
| JP6817069B2 (ja) | 2014-04-25 | 2021-01-20 | ブルーバード バイオ， インコーポレイテッド | 養子細胞療法薬を製造するための改善された方法 |
| LT3134432T (lt) | 2014-04-25 | 2020-04-10 | Bluebird Bio, Inc. | Mnd promotorius chimerinių antigenų receptoriams |
| WO2015182668A1 (ja) * | 2014-05-28 | 2015-12-03 | 学校法人東京女子医科大学 | 膠芽腫の予測方法 |
| JP2015227292A (ja) * | 2014-05-30 | 2015-12-17 | 国立大学法人高知大学 | 膵がん細胞浸潤転移抑制ワクチン |
| CN106793780B (zh) * | 2014-06-06 | 2020-05-26 | 蓝鸟生物公司 | 改善的t细胞组合物 |
| JP6366379B2 (ja) * | 2014-06-20 | 2018-08-01 | キヤノン株式会社 | 被検体情報取得装置 |
| WO2016014789A2 (en) | 2014-07-24 | 2016-01-28 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
| AU2014410466B2 (en) * | 2014-11-06 | 2019-09-12 | Ose Immunotherapeutics | Therapeutic multi-peptides T specific immune therapy for treatment of brain metastasis |
| WO2016094304A2 (en) | 2014-12-12 | 2016-06-16 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
| SI3616706T1 (sl) * | 2014-12-23 | 2021-12-31 | Immatics Biotechnologies Gmbh | Novi peptidi in kombinacija peptidov za uporabo v imunoterapiji proti hepatocelularnem karcinomu (HCC) in drugim oblikam raka |
| GB201501017D0 (en) * | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| GB201423361D0 (en) * | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| MY199500A (en) | 2015-03-17 | 2023-11-01 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
| GB201505585D0 (en) | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| GB201507719D0 (en) * | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| CR20230131A (es) * | 2015-05-06 | 2023-06-23 | Immatics Biotechnologies Gmbh | NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS Y DE SOPORTES PARA LA INMUNOTERAPIA CONTRA EL CARCINOMA COLORRECTAL Y OTROS TIPOS DE CÁNCER (Divisional Exp. 2017-0497) |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| WO2016200787A2 (en) | 2015-06-09 | 2016-12-15 | The Board Of Regents Of The University Of Oklahoma | Compositions and treatments for haemophilus influenzae |
| WO2016207646A1 (en) | 2015-06-24 | 2016-12-29 | Immodulon Therapeutics Limited | A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| MA42294B1 (fr) | 2015-07-01 | 2020-11-30 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers |
| EA201792671A1 (ru) * | 2015-07-06 | 2018-06-29 | Имматикс Байотекнолоджиз Гмбх | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака пищевода и других видов рака |
| GB201512369D0 (en) * | 2015-07-15 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| GB201513921D0 (en) * | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| TWI782434B (zh) | 2015-08-28 | 2022-11-01 | 德商英麥提克生物技術股份有限公司 | 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架 |
| GB201515321D0 (en) | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| US10709758B2 (en) | 2015-09-03 | 2020-07-14 | The Board Of Regents Of The University Of Oklahoma | Peptide inhibitors of clostridium difficile toxin B (TcdB) toxin |
| CN108289909A (zh) | 2015-10-19 | 2018-07-17 | 巴尔的摩马里兰大学 | 用于产生工程改造的人原代血液树突细胞系的方法 |
| WO2017099712A1 (en) | 2015-12-07 | 2017-06-15 | Bluebird Bio, Inc. | Improved t cell compositions |
| GB201521746D0 (en) * | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
| HK1255541A1 (zh) * | 2015-12-11 | 2019-08-23 | Immatics Biotechnologies Gmbh | 用於多种癌症免疫治疗的新型肽和肽组合物 |
| EP4299136A3 (en) | 2015-12-16 | 2024-02-14 | Gritstone bio, Inc. | Neoantigen identification, manufacture, and use |
| US10604759B2 (en) | 2016-01-15 | 2020-03-31 | City Of Hope | Targeting glioblastoma stem cells through the TLX-TET3 axis |
| GB201603568D0 (en) * | 2016-03-01 | 2016-04-13 | Immatics Biotechnologies Gmbh | Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer |
| GB201603987D0 (en) | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| CN109620949A (zh) * | 2016-03-13 | 2019-04-16 | 曹帅 | 一种用于治疗骨癌的药物组合物 |
| GB201604494D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers |
| ES2930681T3 (es) | 2016-03-16 | 2022-12-20 | Immatics Biotechnologies Gmbh | Linfocitos T transfectados y receptores de linfocito T para el uso en la inmunoterapia contra el cáncer |
| GB201604490D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
| BR112018070067A2 (pt) * | 2016-04-06 | 2019-02-12 | Immatics Biotechnologies Gmbh | peptídeos e combinações de peptídeos para uso em imunoterapia contra lma e outros cânceres |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| WO2017194170A1 (en) * | 2016-05-13 | 2017-11-16 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of proteins or protein fragments for immunotherapy |
| KR101881300B1 (ko) | 2016-06-30 | 2018-07-25 | 영남대학교 산학협력단 | 아조피라졸 화합물 및 은 촉매 반응을 이용한 이의 신규한 합성방법 |
| CN110022889B (zh) * | 2016-10-03 | 2024-05-10 | 渥太华医院研究所 | 用于提高溶瘤rna病毒的生长、传播和溶瘤与免疫治疗效果的组合物和方法 |
| MX2019005277A (es) | 2016-11-04 | 2019-09-27 | Bluebird Bio Inc | Composiciones de celulas t con car anti-bcma. |
| EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| ES2973548T3 (es) * | 2016-12-22 | 2024-06-20 | Cue Biopharma Inc | Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso |
| SG11201903021WA (en) | 2017-01-06 | 2019-05-30 | Eutilex Co Ltd | Anti-human 4-1 bb antibodies and use thereof |
| GB201702863D0 (en) * | 2017-02-22 | 2017-04-05 | Evox Therapeutics Ltd | Improved loading of EVs with therapeutic proteins |
| WO2018160498A1 (en) * | 2017-02-28 | 2018-09-07 | Lyten, Inc. | Mixed allotrope particulate carbon films and carbon fiber mats |
| AU2018266705B2 (en) * | 2017-05-08 | 2023-05-04 | Seattle Project Corp. | Alphavirus neoantigen vectors |
| CN107034305A (zh) * | 2017-06-19 | 2017-08-11 | 上海市第十人民医院 | 恶性胶质瘤的一种诊断标志物 |
| CN107058596A (zh) * | 2017-06-19 | 2017-08-18 | 上海市第十人民医院 | 一种与恶性胶质瘤诊断相关的标志物及其应用 |
| EP3694532B1 (en) | 2017-10-10 | 2025-02-26 | Gritstone bio, Inc. | Neoantigen identification using hotspots |
| IL274799B2 (en) | 2017-11-22 | 2025-05-01 | Gritstone Bio Inc | Reducing junction epitope presentation for neoantigens |
| BR112020009889A2 (pt) | 2017-12-14 | 2020-11-03 | Flodesign Sonics, Inc. | acionador e controlador de transdutor acústico |
| WO2019118793A2 (en) * | 2017-12-14 | 2019-06-20 | Ezy Biotech Llc | Subject-specific tumor inhibiting cells and the use thereof |
| LT3773689T (lt) * | 2018-04-11 | 2023-01-25 | Enterome S.A. | Antigeniniai peptidai, skirti vėžio prevencijai ir gydymui |
| CN108715832B (zh) * | 2018-06-01 | 2020-11-10 | 段海峰 | 一种抑制肿瘤生长的间充质干细胞及制备方法和应用 |
| CA3105381A1 (en) | 2018-07-11 | 2020-01-16 | The Brigham And Women's Hospital, Inc. | Methods and compositions for delivery of agents across the blood-brain barrier |
| WO2020110154A1 (en) * | 2018-11-30 | 2020-06-04 | Bharat Biotech International Limited | A chimeric therapeutic vaccine |
| RU2706554C1 (ru) * | 2018-12-13 | 2019-11-19 | Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ | Способ создания противоинфекционной иммунологической защиты к Salmonella typhimurium и Listeria monocytogenes с помощью трансгенеза Т-лимфоцитов |
| CN109796536B (zh) * | 2019-02-22 | 2021-09-17 | 上海尚泰生物技术有限公司 | 一种靶向胶质母细胞瘤多种抗原表位的ctl的制备方法 |
| MX2021011848A (es) | 2019-03-29 | 2021-10-22 | Intervet Int Bv | Estabilizacion de bacterias mollicutes vivas en una composicion liquida. |
| JP2022527629A (ja) * | 2019-04-05 | 2022-06-02 | アーリー・インコーポレイテッド | 合成バイオマーカーのための改良された方法及び組成物 |
| AU2020284538B2 (en) | 2019-05-28 | 2022-03-24 | PAIGE.AI, Inc. | Systems and methods for processing images to prepare slides for processed images for digital pathology |
| BR112021024127A2 (pt) | 2019-05-30 | 2022-04-26 | Gritstone Bio Inc | Adenovírus modificado |
| CN110579457B (zh) * | 2019-09-20 | 2021-11-02 | 郑州大学第一附属医院 | 波形蛋白特异响应性荧光探针及其制备方法和应用 |
| CN112824427B (zh) * | 2019-11-18 | 2022-06-24 | 杨小骏 | 一种抑制胶质瘤的短肽及其应用 |
| CA3167290A1 (en) * | 2020-01-10 | 2021-07-15 | The Brigham And Women's Hospital, Inc. | Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer |
| EP4110354A4 (en) * | 2020-02-24 | 2024-11-13 | The Regents of The University of California | Use of brain-specific antigens to home, block and deliver cell-based treatments to the brain |
| CN113318225B (zh) * | 2020-02-28 | 2024-01-19 | 无锡派列博生物医药科技有限公司 | 肿瘤免疫增强剂及其制法和应用 |
| CN111333698B (zh) * | 2020-03-18 | 2021-11-23 | 北京鼎成肽源生物技术有限公司 | 一种乳腺癌靶标抗原组合、乳腺癌靶标抗原组合刺激培养的ctl细胞及其应用 |
| EP4127188A4 (en) | 2020-03-31 | 2024-08-21 | Walking Fish Therapeutics | MODIFIED B CELLS AND METHODS OF USE THEREOF |
| KR20230006821A (ko) * | 2020-03-31 | 2023-01-11 | 워킹 피쉬 테라퓨틱스 | 변형 b 세포 및 이의 사용 방법 |
| EP4149534A4 (en) | 2020-05-12 | 2024-09-04 | Cue Biopharma, Inc. | MULTIMERIC POLYPEPTIDES MODULATING T CELLS AND METHODS OF USE THEREOF |
| CN116438308A (zh) | 2020-08-06 | 2023-07-14 | 磨石生物公司 | 多表位疫苗盒 |
| KR102711471B1 (ko) | 2020-08-14 | 2024-09-30 | 서울대학교산학협력단 | B형 간염 바이러스 유래 폴리펩티드를 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| EP4203994A4 (en) * | 2020-08-28 | 2024-07-03 | Torigen Pharmaceuticals, Inc. | Immune memory enhanced preparations and uses thereof |
| US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
| US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| CN116710115A (zh) | 2020-11-20 | 2023-09-05 | 思维疗法股份有限公司 | 用于优化的肽疫苗的组合物和方法 |
| CA3212968A1 (en) * | 2021-03-09 | 2022-09-15 | Bostongene Corporation | Predicting response to treatments in patients with clear cell renal cell carcinoma |
| US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
| US20250235517A1 (en) * | 2022-03-30 | 2025-07-24 | Iogenetics, Llc | Tumor-associated antigens in brain tumors |
| PL441229A1 (pl) * | 2022-05-19 | 2023-11-20 | Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk | Zaprojektowane, syntetyczne peptydy, zawierające je kompozycje i sposoby ich zastosowania w leczeniu glejaków złośliwych |
| CN120272531B (zh) * | 2025-06-10 | 2025-08-19 | 鼐济医药科技(杭州)有限公司 | 一种基于aav介导免疫微环境的脑胶质瘤动物模型构建方法 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| IN151589B (enExample) | 1978-12-22 | 1983-05-28 | Biogen Nv | |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
| US5338839A (en) * | 1988-04-12 | 1994-08-16 | Massachusetts Institute Of Technology | DNA encoding nestin protein |
| GB2267257A (en) | 1992-05-14 | 1993-12-01 | Ford Motor Co | A vehicle load compartment liner. |
| KR100235089B1 (en) | 1992-05-14 | 1999-12-15 | Mitsui Chemicals Inc | Ptp or blister packaging articles and packaging material therefor |
| AU6852594A (en) | 1993-06-03 | 1995-01-03 | Therapeutic Antibodies Inc. | Production of antibody fragments |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| WO1997026328A1 (en) | 1996-01-17 | 1997-07-24 | Imperial College Innovations Limited | Immunotherapy using cytotoxic t lymphocytes (ctl) |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| TW575583B (en) * | 1996-04-24 | 2004-02-11 | Akzo Nobel Nv | Novel peptides suitable for use in antigen specific immunosuppressive therapy |
| JP2002513381A (ja) * | 1996-07-22 | 2002-05-08 | ザ ロックフェラー ユニバーシティー | ＨＴＬＶ―Ｉ感染およびＨＴＬＶ―ＩＩ感染を予防するためのｅｎｖ―糖タンパク質ワクチン |
| AU6240798A (en) | 1997-01-15 | 1998-08-07 | Zymogenetics Inc. | Zppar6, human tailless nuclear hormone receptor (tlx receptor) |
| EP0910641A1 (en) * | 1997-02-13 | 1999-04-28 | Smithkline Beecham Plc | Neural cell adhesion molecule splicing variants |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US6682928B2 (en) * | 1997-12-02 | 2004-01-27 | Medarex, Inc. | Cells expressing anti-Fc receptor binding components |
| US7258860B2 (en) * | 1998-03-18 | 2007-08-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US20070004655A9 (en) * | 1998-04-27 | 2007-01-04 | Murphy Gerald P | Nr-cam gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors |
| US6960651B2 (en) * | 1999-06-29 | 2005-11-01 | Millennium Pharmaceuticals, Inc. | TANGO 332 polypeptides |
| CA2392398A1 (en) * | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| US20020042096A1 (en) * | 2000-01-31 | 2002-04-11 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| ATE472601T1 (de) | 2000-03-27 | 2010-07-15 | Technion Res And Dev Of Founda | Einkettige haupthistokompatibilitätskomplexe der klasse i (mhc-i), kodierende konstrukte und methoden ihrer erzeugung |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| EP1317275A1 (de) * | 2000-09-06 | 2003-06-11 | Müller, Friederike | Arzneimittel mit einer für das rna-bindende koc-protein kodierenden dna-sequenz, einem koc-protein oder einer dna-sequenz des koc-promotors |
| EP1356048A2 (en) * | 2000-12-04 | 2003-10-29 | Argonex Pharmaceuticals | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| WO2002046767A2 (en) * | 2000-12-08 | 2002-06-13 | Oxford Glycosciences (Uk) Ltd. | Diagnosis and treatment of alzheimer's disease |
| AU2002254482A1 (en) * | 2001-03-19 | 2002-10-03 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of kidney cancer |
| CA2364106A1 (fr) * | 2001-11-30 | 2003-05-30 | Christopher Gillberg | Polynucleotide et proteine impliques dans la synaptogenese, variants de ceux-ci, et leurs applications therapeutiques et diagnostiques |
| US6589642B1 (en) | 2001-12-21 | 2003-07-08 | Kloeckner Pentaplast Of America, Inc. | Three part high moisture barrier for packages |
| US7892559B2 (en) * | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| US20030223994A1 (en) | 2002-02-20 | 2003-12-04 | Hoogenboom Henricus Renerus Jacobus Mattheus | MHC-peptide complex binding ligands |
| WO2004015390A2 (en) * | 2002-08-09 | 2004-02-19 | Applera Corporation | Lung cancer target proteins and use thereof |
| JP4721633B2 (ja) * | 2002-10-11 | 2011-07-13 | 財団法人癌研究会 | 血小板凝集促進活性を有する物質 |
| JP2006516258A (ja) * | 2002-12-27 | 2006-06-29 | シェンジェンシチンファユアンシンシェンウイヤオカジヨウシャンゴンシ | ワクチンおよび抗腫瘍ワクチンを調製する方法 |
| WO2004089300A2 (en) | 2003-04-04 | 2004-10-21 | Pharmacyclics, Inc. | Sapphyrins and uses thereof |
| US7273980B2 (en) | 2004-01-13 | 2007-09-25 | Wardle Scott A | Position and velocity transducer using a phonograph disc and turntable |
| US7655751B2 (en) * | 2004-01-23 | 2010-02-02 | Green Peptide Co., Ltd. | Epidermal growth factor receptor-derived peptides |
| DE102004026135A1 (de) | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| WO2006026569A2 (en) * | 2004-08-27 | 2006-03-09 | Northeastern University | Comprehensive characterization of complex proteins at trace levels |
| EP1642905B1 (en) * | 2004-10-02 | 2009-01-21 | Immatics Biotechnologies GmbH | Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes |
| EP1835027B1 (en) * | 2004-12-07 | 2015-02-25 | Toray Industries, Inc. | Novel cancer antigen peptide and the use thereof |
| KR100809410B1 (ko) * | 2005-07-06 | 2008-03-05 | 주식회사 브레인가드 | 줄기세포 분화 유도용 조성물 및 그의 용도 |
| ATE461215T1 (de) | 2005-09-05 | 2010-04-15 | Immatics Biotechnologies Gmbh | Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden |
| PT1760089E (pt) * | 2005-09-05 | 2009-10-19 | Immatics Biotechnologies Gmbh | Peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antigénio leucocitário humano (hla) e correspondente vacina anti-cancerígena |
| US20070099251A1 (en) | 2005-10-17 | 2007-05-03 | Institute For Systems Biology | Tissue-and serum-derived glycoproteins and methods of their use |
| US20070248628A1 (en) * | 2005-12-06 | 2007-10-25 | Keller Lorraine H | Immunogens in cancer stem cells |
| WO2007072494A1 (en) | 2005-12-23 | 2007-06-28 | Naik Praful Ramchandra | Metallized packaging blister container |
| CA2665816C (en) * | 2006-09-21 | 2016-07-12 | Vaxil Biotherapeutics Ltd. | Antigen specific multi epitope vaccines |
| EP2084267B1 (en) * | 2006-09-26 | 2018-04-11 | Cedars-Sinai Medical Center | Cancer stem cell antigen vaccines and methods |
| WO2008109757A2 (en) * | 2007-03-06 | 2008-09-12 | Iterative Therapeutics, Inc. | Methods and compositions involving polymeric immunoglobulin fusion proteins |
| WO2009125394A1 (en) * | 2008-04-09 | 2009-10-15 | Technion Research & Development Foundation Ltd. | Anti human immunodeficiency antibodies and uses thereof |
| KR101184869B1 (ko) | 2008-04-24 | 2012-09-20 | 이매틱스 바이오테크놀로지스 게엠베하 | 백신을 위한 인간 조직 적합성 항원(ｈｌａ) 종류 ｉ 또는 ｉｉ 분자에 결합하는 종양 관련 펩티드의 신규한 제형 |
| DE602008000891D1 (de) * | 2008-04-30 | 2010-05-12 | Immatics Biotechnologies Gmbh | Neuartige Formulierungen von Tumor-assoziierten Peptiden, welche an menschliche Leukozytenantigene der Klasse I oder II für Impfungen binden |
| EP2172211B1 (en) | 2008-10-01 | 2014-12-03 | Immatics Biotechnologies GmbH | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201021289D0 (en) | 2010-12-15 | 2011-01-26 | Immatics Biotechnologies Gmbh | Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer |
| PT3149048T (pt) * | 2014-05-28 | 2020-04-21 | Nono Inc | Formulação liofilizada de tat-nr2b9c |
| SG11201808629UA (en) | 2016-04-21 | 2018-11-29 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
| JP7382310B2 (ja) * | 2017-09-06 | 2023-11-16 | カリフォルニア インスティチュート オブ テクノロジー | シグナリング及び抗原提示の２機能性レセプター（ｓａｂｒ） |
-
2008
- 2008-10-01 EP EP20080017305 patent/EP2172211B1/en active Active
- 2008-10-01 SI SI200831373T patent/SI2172211T1/sl unknown
- 2008-10-01 DK DK08017305T patent/DK2172211T3/en active
- 2008-10-01 PL PL08017305T patent/PL2172211T3/pl unknown
- 2008-10-01 RS RS20150094A patent/RS53782B1/sr unknown
- 2008-10-01 ES ES08017305.7T patent/ES2536465T3/es active Active
- 2008-10-01 PT PT80173057T patent/PT2172211E/pt unknown
- 2008-10-13 EP EP08017921.1A patent/EP2172212B1/en active Active
- 2008-10-13 SI SI200831695A patent/SI2172212T1/sl unknown
- 2008-10-13 LT LTEP08017921.1T patent/LT2172212T/lt unknown
- 2008-10-13 ES ES08017921.1T patent/ES2607460T3/es active Active
- 2008-10-13 PL PL08017921T patent/PL2172212T3/pl unknown
- 2008-10-13 PT PT80179211T patent/PT2172212T/pt unknown
- 2008-10-13 RS RS20161019A patent/RS55543B1/sr unknown
- 2008-10-13 DK DK08017921.1T patent/DK2172212T3/da active
- 2008-10-13 HU HUE08017921A patent/HUE031030T2/en unknown
-
2009
- 2009-09-28 DK DK16179163.7T patent/DK3106175T3/da active
- 2009-09-28 PL PL16165070T patent/PL3069728T3/pl unknown
- 2009-09-28 RS RS20200692A patent/RS60385B1/sr unknown
- 2009-09-28 NZ NZ591855A patent/NZ591855A/xx not_active IP Right Cessation
- 2009-09-28 EP EP16179174.4A patent/EP3120868B1/en active Active
- 2009-09-28 RS RS20190118A patent/RS58443B1/sr unknown
- 2009-09-28 PT PT161791744T patent/PT3120868T/pt unknown
- 2009-09-28 PT PT97787501T patent/PT2341927T/pt unknown
- 2009-09-28 AU AU2009300088A patent/AU2009300088B2/en not_active Ceased
- 2009-09-28 LT LTEP16179163.7T patent/LT3106175T/lt unknown
- 2009-09-28 KR KR1020117010000A patent/KR101687840B1/ko not_active Expired - Fee Related
- 2009-09-28 UA UAA201103611A patent/UA110599C2/uk unknown
- 2009-09-28 LT LTEP09778749.3T patent/LT2331118T/lt unknown
- 2009-09-28 RS RS20200693A patent/RS60386B1/sr unknown
- 2009-09-28 CA CA2936982A patent/CA2936982C/en active Active
- 2009-09-28 HU HUE16179192A patent/HUE050428T2/hu unknown
- 2009-09-28 LT LTEP16179174.4T patent/LT3120868T/lt unknown
- 2009-09-28 EP EP16165070.0A patent/EP3069728B1/en active Active
- 2009-09-28 RS RS20161160A patent/RS55531B1/sr unknown
- 2009-09-28 PL PL09778750.1T patent/PL2341927T3/pl unknown
- 2009-09-28 EP EP09778750.1A patent/EP2341927B1/en active Active
- 2009-09-28 KR KR1020117010003A patent/KR101756488B1/ko not_active Expired - Fee Related
- 2009-09-28 PL PL16179214T patent/PL3124043T3/pl unknown
- 2009-09-28 CN CN201610831523.XA patent/CN106986919A/zh active Pending
- 2009-09-28 LT LTEP16179214.8T patent/LT3124043T/lt unknown
- 2009-09-28 BR BRPI0920791A patent/BRPI0920791B8/pt not_active IP Right Cessation
- 2009-09-28 EP EP16179214.8A patent/EP3124043B1/en active Active
- 2009-09-28 EA EA201100586A patent/EA023013B1/ru unknown
- 2009-09-28 ES ES16179169T patent/ES2770090T3/es active Active
- 2009-09-28 DK DK16165070.0T patent/DK3069728T3/en active
- 2009-09-28 HR HRP20160915TT patent/HRP20160915T1/hr unknown
- 2009-09-28 ES ES16179163T patent/ES2802226T3/es active Active
- 2009-09-28 DK DK09778749.3T patent/DK2331118T5/da active
- 2009-09-28 CA CA2739387A patent/CA2739387C/en active Active
- 2009-09-28 EA EA201401104A patent/EA032437B1/ru unknown
- 2009-09-28 PL PL16179169T patent/PL3132801T3/pl unknown
- 2009-09-28 LT LTEP16165070.0T patent/LT3069728T/lt unknown
- 2009-09-28 EP EP16179241.1A patent/EP3111952B1/en active Active
- 2009-09-28 DK DK16179192.6T patent/DK3120869T3/da active
- 2009-09-28 HR HRP20170115TT patent/HRP20170115T1/hr unknown
- 2009-09-28 SI SI200932063T patent/SI3106175T1/sl unknown
- 2009-09-28 DK DK16179214.8T patent/DK3124043T3/da active
- 2009-09-28 SI SI200932056T patent/SI3124043T1/sl unknown
- 2009-09-28 CA CA2936869A patent/CA2936869C/en active Active
- 2009-09-28 HU HUE16179169A patent/HUE047365T2/hu unknown
- 2009-09-28 CA CA2936868A patent/CA2936868C/en active Active
- 2009-09-28 PL PL16179192T patent/PL3120869T3/pl unknown
- 2009-09-28 RS RS20200691A patent/RS60381B1/sr unknown
- 2009-09-28 WO PCT/EP2009/006979 patent/WO2010037513A1/en not_active Ceased
- 2009-09-28 PL PL16179241T patent/PL3111952T3/pl unknown
- 2009-09-28 DK DK16179174.4T patent/DK3120868T3/da active
- 2009-09-28 HU HUE16165070A patent/HUE041446T2/hu unknown
- 2009-09-28 HR HRP20201025TT patent/HRP20201025T8/hr unknown
- 2009-09-28 SI SI200931464A patent/SI2341927T1/sl unknown
- 2009-09-28 CA CA2739384A patent/CA2739384C/en not_active Expired - Fee Related
- 2009-09-28 HU HUE16179174A patent/HUE049366T2/hu unknown
- 2009-09-28 HU HUE16179226A patent/HUE049364T2/hu unknown
- 2009-09-28 RS RS20181585A patent/RS58229B1/sr unknown
- 2009-09-28 MX MX2011003539A patent/MX2011003539A/es active IP Right Grant
- 2009-09-28 ES ES16179174T patent/ES2804723T3/es active Active
- 2009-09-28 PT PT161791637T patent/PT3106175T/pt unknown
- 2009-09-28 KR KR1020167022929A patent/KR101883426B1/ko active Active
- 2009-09-28 PL PL16179163T patent/PL3106175T3/pl unknown
- 2009-09-28 CA CA2936924A patent/CA2936924C/en active Active
- 2009-09-28 RS RS20200512A patent/RS60338B1/sr unknown
- 2009-09-28 HU HUE16179214A patent/HUE051030T2/hu unknown
- 2009-09-28 ES ES16179192T patent/ES2819244T3/es active Active
- 2009-09-28 RS RS20160553A patent/RS55043B1/sr unknown
- 2009-09-28 ES ES16179241T patent/ES2708654T3/es active Active
- 2009-09-28 SI SI200931902T patent/SI3111952T1/sl unknown
- 2009-09-28 PL PL16179174T patent/PL3120868T3/pl unknown
- 2009-09-28 ES ES16165070T patent/ES2710608T3/es active Active
- 2009-09-28 PT PT161791926T patent/PT3120869T/pt unknown
- 2009-09-28 MX MX2011003540A patent/MX2011003540A/es active IP Right Grant
- 2009-09-28 ES ES16179214T patent/ES2788129T3/es active Active
- 2009-09-28 EP EP16179226.2A patent/EP3120870B1/en active Active
- 2009-09-28 PL PL09778749T patent/PL2331118T3/pl unknown
- 2009-09-28 RS RS20200973A patent/RS60656B1/sr unknown
- 2009-09-28 PT PT16179241T patent/PT3111952T/pt unknown
- 2009-09-28 DK DK16179241.1T patent/DK3111952T3/en active
- 2009-09-28 DK DK16179169.4T patent/DK3132801T3/da active
- 2009-09-28 LT LTEP16179192.6T patent/LT3120869T/lt unknown
- 2009-09-28 LT LTEP16179241.1T patent/LT3111952T/lt unknown
- 2009-09-28 CA CA2936870A patent/CA2936870C/en active Active
- 2009-09-28 RS RS20200085A patent/RS60006B1/sr unknown
- 2009-09-28 AU AU2009300087A patent/AU2009300087B2/en not_active Ceased
- 2009-09-28 SI SI200932064T patent/SI3120870T1/sl unknown
- 2009-09-28 EP EP16179169.4A patent/EP3132801B1/en active Active
- 2009-09-28 HU HUE16179163A patent/HUE049367T2/hu unknown
- 2009-09-28 PT PT16165070T patent/PT3069728T/pt unknown
- 2009-09-28 CA CA2936920A patent/CA2936920C/en active Active
- 2009-09-28 HU HUE16179241A patent/HUE042115T2/hu unknown
- 2009-09-28 DK DK09778750.1T patent/DK2341927T3/en active
- 2009-09-28 HU HUE09778749A patent/HUE030296T2/en unknown
- 2009-09-28 NZ NZ603016A patent/NZ603016A/en not_active IP Right Cessation
- 2009-09-28 SI SI200931573A patent/SI2331118T1/sl unknown
- 2009-09-28 KR KR1020187021349A patent/KR102133402B1/ko active Active
- 2009-09-28 UA UAA201500916A patent/UA125277C2/uk unknown
- 2009-09-28 SI SI200931921T patent/SI3069728T1/sl unknown
- 2009-09-28 PT PT161791694T patent/PT3132801T/pt unknown
- 2009-09-28 TR TR2019/00809T patent/TR201900809T4/tr unknown
- 2009-09-28 SI SI200932034T patent/SI3132801T1/sl unknown
- 2009-09-28 CN CN200980139419.2A patent/CN102170900B/zh active Active
- 2009-09-28 EA EA201100587A patent/EA023378B1/ru unknown
- 2009-09-28 CN CN200980139420.5A patent/CN102170901B/zh not_active Expired - Fee Related
- 2009-09-28 EP EP16179163.7A patent/EP3106175B1/en active Active
- 2009-09-28 NZ NZ624533A patent/NZ624533A/en not_active IP Right Cessation
- 2009-09-28 EP EP16179192.6A patent/EP3120869B1/en active Active
- 2009-09-28 PL PL16179226T patent/PL3120870T3/pl unknown
- 2009-09-28 ES ES09778749.3T patent/ES2612466T3/es active Active
- 2009-09-28 NZ NZ591882A patent/NZ591882A/xx not_active IP Right Cessation
- 2009-09-28 JP JP2011529472A patent/JP5855940B2/ja not_active Expired - Fee Related
- 2009-09-28 EP EP09778749.3A patent/EP2331118B1/en active Active
- 2009-09-28 CA CA2936887A patent/CA2936887C/en active Active
- 2009-09-28 MX MX2012012047A patent/MX338294B/es unknown
- 2009-09-28 BR BRPI0920759A patent/BRPI0920759A2/pt not_active Application Discontinuation
- 2009-09-28 SI SI200932083T patent/SI3120869T1/sl unknown
- 2009-09-28 PT PT97787493T patent/PT2331118T/pt unknown
- 2009-09-28 SI SI200932065T patent/SI3120868T1/sl unknown
- 2009-09-28 KR KR1020207019579A patent/KR102392070B1/ko active Active
- 2009-09-28 PT PT161792148T patent/PT3124043T/pt unknown
- 2009-09-28 UA UAA201103612A patent/UA103202C2/ru unknown
- 2009-09-28 DK DK16179226.2T patent/DK3120870T3/da active
- 2009-09-28 ES ES16179226T patent/ES2802227T3/es active Active
- 2009-09-28 PT PT161792262T patent/PT3120870T/pt unknown
- 2009-09-28 ES ES09778750.1T patent/ES2584245T3/es active Active
- 2009-09-28 WO PCT/EP2009/006980 patent/WO2010037514A2/en not_active Ceased
- 2009-09-28 KR KR1020227013879A patent/KR20220058655A/ko not_active Ceased
- 2009-09-28 LT LTEP16179169.4T patent/LT3132801T/lt unknown
- 2009-09-28 HU HUE09778750A patent/HUE029360T2/en unknown
- 2009-09-28 JP JP2011529471A patent/JP5753783B2/ja not_active Expired - Fee Related
- 2009-09-28 LT LTEP16179226.2T patent/LT3120870T/lt unknown
- 2009-09-28 TR TR2019/00852T patent/TR201900852T4/tr unknown
- 2009-10-01 US US12/571,602 patent/US8318677B2/en active Active
- 2009-10-01 US US12/571,776 patent/US8119139B2/en active Active
-
2012
- 2012-01-09 US US13/346,598 patent/US8961985B2/en active Active
- 2012-08-17 US US13/588,206 patent/US8653035B2/en active Active
-
2013
- 2013-03-15 US US13/841,013 patent/US8895514B2/en active Active
-
2014
- 2014-06-19 JP JP2014126001A patent/JP5883476B2/ja not_active Expired - Fee Related
- 2014-12-05 US US14/562,156 patent/US10227381B2/en active Active
-
2015
- 2015-02-12 CY CY20151100139T patent/CY1116302T1/el unknown
- 2015-02-26 HR HRP20150223TT patent/HRP20150223T8/hr unknown
- 2015-10-08 JP JP2015200021A patent/JP6150859B2/ja active Active
-
2016
- 2016-02-05 JP JP2016021002A patent/JP6214066B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136519A patent/JP6297632B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136515A patent/JP6367266B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136518A patent/JP6294914B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136517A patent/JP6294913B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136516A patent/JP2017029135A/ja active Pending
- 2016-08-02 US US15/226,206 patent/US10047124B2/en active Active
- 2016-08-02 US US15/226,098 patent/US10906936B2/en not_active Expired - Fee Related
- 2016-08-02 US US15/226,002 patent/US10047123B2/en active Active
- 2016-08-02 US US15/226,126 patent/US10919931B2/en not_active Expired - Fee Related
- 2016-08-02 US US15/226,038 patent/US10100085B2/en active Active
- 2016-08-02 US US15/226,161 patent/US10941181B2/en not_active Expired - Fee Related
- 2016-08-02 CY CY20161100759T patent/CY1119744T1/el unknown
- 2016-08-02 US US15/226,081 patent/US10046037B2/en active Active
- 2016-11-15 HR HRP20161504TT patent/HRP20161504T1/hr unknown
-
2017
- 2017-01-26 CY CY20171100124T patent/CY1118702T1/el unknown
- 2017-06-30 US US15/638,806 patent/US9993540B2/en active Active
-
2018
- 2018-09-19 US US16/136,008 patent/US20190010190A1/en not_active Abandoned
- 2018-12-18 HR HRP20182151TT patent/HRP20182151T1/hr unknown
- 2018-12-28 CY CY181101403T patent/CY1121098T1/el unknown
-
2019
- 2019-01-31 HR HRP20190202TT patent/HRP20190202T1/hr unknown
- 2019-02-12 CY CY20191100182T patent/CY1121258T1/el unknown
-
2020
- 2020-01-23 HR HRP20200110TT patent/HRP20200110T1/hr unknown
- 2020-01-28 CY CY20201100073T patent/CY1122677T1/el unknown
- 2020-05-05 HR HRP20200722TT patent/HRP20200722T1/hr unknown
- 2020-05-15 CY CY20201100449T patent/CY1122913T1/el unknown
- 2020-06-19 HR HRP20200988TT patent/HRP20200988T1/hr unknown
- 2020-06-26 HR HRP20201015TT patent/HRP20201015T8/hr unknown
- 2020-06-26 CY CY20201100594T patent/CY1123089T1/el unknown
- 2020-06-30 CY CY20201100606T patent/CY1123098T1/el unknown
- 2020-07-03 CY CY20201100613T patent/CY1123113T1/el unknown
- 2020-08-06 HR HRP20201228TT patent/HRP20201228T1/hr unknown
- 2020-10-19 CY CY20201100984T patent/CY1123526T1/el unknown
-
2021
- 2021-04-23 US US17/238,787 patent/US12234298B2/en active Active
- 2021-04-23 US US17/238,840 patent/US11136352B2/en active Active
- 2021-04-23 US US17/238,806 patent/US12221493B2/en active Active
- 2021-07-23 US US17/384,152 patent/US11208434B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012504393A5 (enExample) | ||
| JP2017502076A5 (enExample) | ||
| JP2011520436A5 (enExample) | ||
| KR101391561B1 (ko) | Ｈｌａ-ａ*3303 구속성 ｗｔ1 펩티드, 및 그것을 포함하는 의약 조성물 | |
| TWI608099B (zh) | 用於活化細胞毒性ｔ細胞的方法及組成物，及用於細胞毒性ｔ細胞之活化誘導物 | |
| JP2020182458A5 (enExample) | ||
| HRP20161504T1 (hr) | Nova imunoterapija protiv nekoliko tumora uključujući neuronske tumore i tumore mozga | |
| JP2018510628A5 (enExample) | ||
| JP2010534464A5 (enExample) | ||
| JP2019511214A5 (enExample) | ||
| HRP20202019T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora | |
| JP2021101700A5 (enExample) | ||
| RU2020113032A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| TW202110875A (zh) | 病毒載體及其在授受性細胞療法之應用 | |
| HRP20210698T1 (hr) | Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma | |
| JP2018511321A5 (enExample) | ||
| JP2018509163A5 (enExample) | ||
| WO2014098012A1 (ja) | ヘルパーt細胞の活性化方法 | |
| Cho et al. | Design of immunogenic and effective multi-epitope DNA vaccines for melanoma | |
| JP2019515653A5 (enExample) | ||
| CN106243213B (zh) | 一种肿瘤相关抗原XAGE-1b短肽及应用 | |
| Bojarska et al. | Short Peptides as Powerful Arsenal for Smart Fighting Cancer | |
| TW202140539A (zh) | 一種辨識ａｆｐ抗原短鏈胜肽的ｔ細胞受體及其編碼序列 | |
| CN101041816B (zh) | 人工抗原递呈细胞及其制备方法 | |
| WO2021139699A1 (zh) | 一种识别afp的t细胞受体及其编码序列 |